AI Article Synopsis
- The study focuses on the treatment of elderly patients (≥75 years) with aneurysmal subarachnoid hemorrhage (aSAH) and investigates factors influencing their outcomes.
- It analyzed 202 patients from nine stroke centers, highlighting that older age, pre-existing health conditions, and severe neurological status at admission correlate with poorer outcomes, while cilostazol treatment showed a positive effect.
- Cilostazol is linked to better recovery rates and reduced instances of delayed cerebral infarction, indicating its potential as a beneficial treatment for elderly aSAH patients.
Article Abstract
Background: The opportunities to treat elderly patients with aneurysmal subarachnoid hemorrhage (aSAH) are increasing globally, but the outcome remains poor. This study seeks to investigate treatment-related factors that can modify functional outcomes in patients with aSAH aged ≥75 years.
Methods: A total of 202 patients with aSAH aged ≥75 years prospectively enrolled in 9 primary stroke centers from 2013 to 2021 were retrospectively analyzed. Clinical variables including treatments for hydrocephalus, angiographic vasospasm, and delayed cerebral ischemia were compared between patients with good (modified Rankin Scale [mRS] score 0-2) and poor (mRS score 3-6) outcomes at 90 days from onset, followed by multivariate analyses to find independent outcome determinants. A modifiable treatment-related variable was evaluated after propensity score matching with adjustments for age, sex, pre-onset mRS score, aSAH severity, and treatment modality.
Results: More than half of patients showed World Federation of Neurological Societies grades IV-V on admission. Univariate analyses showed that advanced age, worse pre-onset mRS score, more severe neurologic status on admission, higher modified Fisher grade on admission computed tomography scans, and acute and chronic hydrocephalus were associated with poor outcomes. In contrast, administration of a phosphodiesterase type III inhibitor, cilostazol, was associated with good outcomes in both univariate (P = 0.036) and multivariate analyses (adjusted odds ratio, 0.305; 95% confidence interval, 0.097-0.955; P = 0.042). Propensity score matching analyses showed that patients treated with cilostazol had better outcomes (P = 0.016) with fewer incidences of delayed cerebral infarction (P = 0.008).
Conclusions: Even in patients with aSAH aged ≥75 years, cilostazol administration may lead to better outcomes by suppressing the development of delayed cerebral infarction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.wneu.2023.10.039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Beyond traditional prognostics: integrating RAG-enhanced AtlasGPT and ChatGPT 4.0 into aneurysmal subarachnoid hemorrhage outcome prediction.
Neurosurg Rev
January 2025
Department of Neurosurgery, University Hospital Leipzig, Leipzig, Saxony, Germany.
To assess the predictive accuracy of advanced AI language models and established clinical scales in prognosticating outcomes for patients with aneurysmal subarachnoid hemorrhage (aSAH). This retrospective cohort study included 82 patients suffering from aSAH. We evaluated the predictive efficacy of AtlasGPT and ChatGPT 4.
View Article and Find Full Text PDFPrognostic Value of Serum Bilirubin in Aneurysmal Subarachnoid Hemorrhage Patients.
Curr Neurovasc Res
January 2025
Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Background: Bilirubin plays a crucial role in the pathophysiological processes of strokes. However, the relationship between serum bilirubin levels and the prognosis of aneurysmal subarachnoid hemorrhage (aSAH) remains unexplored. This study aims to investigate the association between serum bilirubin levels and the mortality rate of aSAH patients.
View Article and Find Full Text PDFShunt-Dependent Hydrocephalus After Aneurysmal Subarachnoid Hemorrhage: Investigation of Prognostic Variables and Creation of a Stronger Predictive Model.
World Neurosurg
January 2025
Department of Neurosurgery, Emory University School of Medicine, 1365 Clifton Road NE, Ste. B6200, Atlanta, Georgia, USA 30322; Radiology and Imaging Sciences, Division of Interventional Neuroradiology, Emory University School of Medicine, 1364 Clifton Road NE, AG26, Atlanta, Georgia, USA, 30322.
Background: Aneurysmal subarachnoid hemorrhage (aSAH) is frequently complicated by permanent shunt-dependent hydrocephalus, but it is difficult to predict which patients are at highest risk.
Objective: This study seeks to identify novel variables associated with shunt dependency after aSAH and to create a predictive algorithm that improves upon existing models.
Methods: Retrospective case control design was used.
Early Microcirculatory Dysfunction on Perfusion CT Is Related to Prognosis After Aneurysmal Subarachnoid Hemorrhage.
Transl Stroke Res
January 2025
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, No.119 South 4 Ring West Road, Beijing, 100070, Fengtai District, China.
Microcirculatory dysfunction is an important pathophysiology mechanism of early brain injury after aneurysmal subarachnoid hemorrhage (aSAH), which contributes to poor outcomes. The study was performed in Beijing Tiantan Hospital from October 2020 to July 2023. Patients with aSAH who underwent computed tomographic perfusion (CTP) within 24 h after ictus were enrolled prospectively.
View Article and Find Full Text PDFThe Impact of Socioeconomic Status on Decision on Withdrawal of Life-sustaining Treatments in Aneurysmal Subarachnoid Hemorrhage.
Neurocrit Care
January 2025
Department of Neurology, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA.
Background: Socioeconomic status affects outcomes in cerebrovascular disease, although its role in the withdrawal of life-sustaining treatments (WLST) remains uncertain. We aim to examine the impact of socioeconomic factors on outcomes including WLST in aneurysmal subarachnoid hemorrhage (aSAH).
Methods: We conducted a retrospective study of a cohort of consecutive patients with aSAH who were admitted to an academic center from 2016 to 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!